Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marloes Schaddelee

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|February 20, 2013
D optimal designs for three Poisson dose-response modelsAlan Maloney, Ulrika S H Simonsson, Marloes Schaddelee
Journal of Pharmacokinetics and Pharmacodynamics|September 28, 2010
An example of optimal phase II design for exposure response modellingAlan Maloney, Marloes Schaddelee, Jan Freijer, et al.
Clinical Therapeutics|March 8, 2016
The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction StudyDorien Groenendaal-van de Meent, Martin den Adel, Sanne Rijnders, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 4, 2013
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprololWalter Krauwinkel, James Dickinson, Marloes Schaddelee, et al.
Clinical Pharmacology in Drug Development|February 19, 2022
Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover StudiesDorien Groenendaal-van de Meent, Martin den Adel, Virginie Kerbusch, et al.
Clinical Therapeutics|May 8, 2021
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy IndividualsDorien Groenendaal-van de Meent, Virginie Kerbusch, Begona Barroso-Fernandez, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 13, 2018
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy SubjectsDorien Groenendaal-van de Meent, Martin den Adel, Jan van Dijk, et al.
Clinical Therapeutics|October 16, 2012
Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and womenWalter Krauwinkel, Jan van Dijk, Marloes Schaddelee, et al.
Clinical Drug Investigation|June 29, 2016
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase InhibitorDorien Groenendaal-van de Meent, Martin den Adel, Jan Noukens, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 25, 2012
Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteersShin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Pharmacokinetics and Pharmacodynamics|February 20, 2013
D optimal designs for three Poisson dose-response modelsAlan Maloney, Ulrika S H Simonsson, Marloes Schaddelee
Journal of Pharmacokinetics and Pharmacodynamics|September 28, 2010
An example of optimal phase II design for exposure response modellingAlan Maloney, Marloes Schaddelee, Jan Freijer, et al.
Clinical Therapeutics|March 8, 2016
The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction StudyDorien Groenendaal-van de Meent, Martin den Adel, Sanne Rijnders, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 4, 2013
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprololWalter Krauwinkel, James Dickinson, Marloes Schaddelee, et al.
Clinical Pharmacology in Drug Development|February 19, 2022
Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover StudiesDorien Groenendaal-van de Meent, Martin den Adel, Virginie Kerbusch, et al.
Clinical Therapeutics|May 8, 2021
Effect of the Phosphate Binders Sevelamer Carbonate and Calcium Acetate on the Pharmacokinetics of Roxadustat After Concomitant or Time-separated Administration in Healthy IndividualsDorien Groenendaal-van de Meent, Virginie Kerbusch, Begona Barroso-Fernandez, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 13, 2018
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy SubjectsDorien Groenendaal-van de Meent, Martin den Adel, Jan van Dijk, et al.
Clinical Therapeutics|October 16, 2012
Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and womenWalter Krauwinkel, Jan van Dijk, Marloes Schaddelee, et al.
Clinical Drug Investigation|June 29, 2016
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase InhibitorDorien Groenendaal-van de Meent, Martin den Adel, Jan Noukens, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 25, 2012
Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteersShin Takusagawa, Jan Jaap van Lier, Katsuhiro Suzuki, et al.
Pageof 2